Screener
Asset Entities ASST Medical Device — Change in fair value
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Asset Entities in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss.
The source filing: Asset Entities’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054985
| Line item | Successor / Three Months Ended June 30, 2026 | Predecessor / Three Months Ended June 30, 2025 |
|---|---|---|
| Total operating expenses | 24,396 | 5,201 |
| Investment losses: | ||
| Net unrealized loss on digital assets, at fair value | (228,031) | — |
| Net unrealized loss on investments in preferred equity, at fair value | (5,962) | — |
| Other investment loss | (2,801) | — |
| Total investment losses | (236,794) | — |
| Net operating loss | (258,249) | (3,690) |
| Other income/(expense): |
Item 1. Consolidated Financial Statements
FAQ
- What is Asset Entities's medical device — change in fair value?
- Asset Entities (ASST) reported medical device — change in fair value of $0 in Q2 2026.
- What does medical device — change in fair value mean?
- This metric captures the periodic adjustments in the valuation of assets or liabilities held by the segment that are marked to market. It reflects unrealized gains or losses resulting from market fluctuations or revaluations of specific holdings. This figure highlights the volatility and financial risk associated with the segment's asset portfolio.
Ask your AI about Asset Entities's medical device — change in fair value.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude